on 'Generic'

1-20 of 30 < first | prev | | last >
  • Biosimilars are coming to LATAM

    There is a flourishing biosimilar industry in Latin America, with its own research, development, production and commercialization capacity

    Franco A. Cucchiaro, International Trade and Supply Chain Pharma Specialist
  • Will product drift cause a rift?

    It’s important to consider how product drift will impact biosimilars

    Ha Kung Wong, Partner, Venable Fitzpatrick’s Intellectual Property Litigation Practice
  • Pharma shoots for the moon

    Reaching new frontiers will require both strategic and financial planning

    Karen Langhauser, Chief Content Director
  • Race to the biosimilar space

    Pharma navigates unfriendly terrain to reach the next frontier in affordable drugs

    Karen Langhauser, Chief Content Director
  • Generics Surge Forward

    AAM Access! 2019 makes it clear that generics have earned their seat at the table

    Karen Langhauser, Chief Content Director
  • Generic But Mighty

    Industry underdogs look giant challenges in the eye

    Karen Langhauser, Chief Content Director
  • ANDA Tips From the FDA

    How the generic drug industry can submit more complete applications

    Renu Lal, Pharm.D., CDER’s Small Business and Industry Assistance (SBIA), Division of Drug Information (DDI), and Lisa Bercu, Regulatory Counsel, CDER’s Office of Generic Drugs (OGD)
  • FDA Clears Hurdles in Generics Race

    Although FDA can’t control prescription drug pricing, it can and will facilitate increased drug competition through faster approval of lower-cost, generic medicines

    Katie Weiler, Managing Editor
  • Embracing the Antihero

    Often vilified, authorized generics can be the silent protectors of profits

    Karen Langhauser, Chief Content Director
  • In Defense of the Anti-Generic

    Authorized generics are the controversial hero of post-patent profitability

    Doug Bartholomew, Contributing Editor
  • GDUFA, Take II

    GDUFA’s second iteration emerges from backlogs and negotiations, promising speed, clarity and transparency

    Karen Langhauser, Chief Content Director
  • 5 Strategies for Generic Supply Chains

    What leading companies are doing to drive holistic improvements across their complex supply chains

    Andrew Gonce, Xin Huang, Jordan Levine and Martin Lösch, McKinsey & Company
  • The Rise of Biosimilars

    North America and Europe will dominate the global biosimilars market as demand rises for these products

    Nigel Walker, Managing Director, That’s Nice / Nice Insight
  • Pros and Cons of Biosimilars

    There are a number of points of view and opinions on how good or necessary biosimilars actually are

    Emil W. Ciurczak, Contributing Editor
  • The State of the Pharma Packaging Industry

    Several factors converging at once for the pharmaceutical industry are contributing to the growth and importance placed on packaging

    Jorge Izquierdo, vp, market development for PMMI, The Association for Packaging and Processing Technologies
1-20 of 30 < first | prev | | last >